{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:49:05Z","timestamp":1793638145376,"version":"4.5.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000261","name":"MS Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000261","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002808","name":"Carlsbergfondet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002808","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2026.e00923","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T12:26:17Z","timestamp":1778761577000},"page":"e00923","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Investigations of remibrutinib in models pertinent to multiple sclerosis"],"prefix":"10.1016","volume":"23","author":[{"given":"Rajiv W.","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atefeh","family":"Rayatpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene T.","family":"Morch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurleen","family":"Randhawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mobarakabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cenxiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Nakhaei-Nejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"Giuliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cenni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhou","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Wee","family":"Yong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10422","key":"10.1016\/j.neurot.2026.e00923_bib1","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0140-6736(23)01473-3","article-title":"Multiple sclerosis","volume":"403","author":"Jakimovski","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib2","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis","volume":"18","author":"Yong","year":"2022","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00923_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q","article-title":"Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination","volume":"47","author":"Lucchinetti","year":"2000","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00923_bib4","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41591-025-03625-7","article-title":"Broad rim lesions are a new pathological and imaging biomarker for rapid disease progression in multiple sclerosis","volume":"31","author":"Klotz","year":"2025","journal-title":"Nat Med"},{"issue":"21","key":"10.1016\/j.neurot.2026.e00923_bib5","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1016\/j.neuron.2022.06.023","article-title":"Microglia in multiple sclerosis: protectors turn destroyers","volume":"110","author":"Yong","year":"2022","journal-title":"Neuron"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00923_bib6","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41577-021-00652-6","article-title":"B cells in central nervous system disease: diversity, locations and pathophysiology","volume":"22","author":"Jain","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.neurot.2026.e00923_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17562864241233041","article-title":"A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis","volume":"17","author":"Airas","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00923_bib8","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s40263-022-00951-z","article-title":"Bruton's tyrosine kinase inhibitors in multiple sclerosis: pioneering the path towards treatment of progression?","volume":"36","author":"Geladaris","year":"2022","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib9","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton's tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00923_bib10","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.4049\/jimmunol.1701489","article-title":"Bruton's tyrosine kinase is not essential for B cell survival beyond early developmental stages","volume":"200","author":"Nyhoff","year":"2018","journal-title":"J Immunol"},{"key":"10.1016\/j.neurot.2026.e00923_bib11","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.3389\/fimmu.2017.01454","article-title":"Bruton's tyrosine kinase: an emerging key player in innate immunity","volume":"8","author":"Weber","year":"2017","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00923_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073461","article-title":"Microglia: the missing link to decipher and therapeutically control MS progression?","volume":"22","author":"Geladaris","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00923_bib13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200413","article-title":"Bruton tyrosine kinase in lesions of multiple sclerosis and 3 of its models","volume":"12","author":"Li","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00923_bib14","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kramer","year":"2023","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurot.2026.e00923_bib15","series-title":"Efficacy and safety of evobrutinib versus teriflunomide in relapsing multiple sclerosis: results from the phase 3 evolution RMS 1 and 2 trials","author":"Montalban","year":"2024"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00923_bib16","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","article-title":"Tolebrutinib versus teriflunomide in relapsing multiple sclerosis","volume":"392","author":"Oh","year":"2025","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00923_bib17","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","article-title":"Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis","volume":"392","author":"Fox","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-024-02730-0","article-title":"BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair","volume":"147","author":"Geladaris","year":"2024","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00923_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/BPL-200100","article-title":"Bruton's tyrosine kinase inhibition promotes Myelin repair","volume":"5","author":"Martin","year":"2020","journal-title":"Brain Plast"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00923_bib20","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00401-020-02204-z","article-title":"Inhibition of Bruton's tyrosine kinase interferes with pathogenic B-cell development in inflammatory CNS demyelinating disease","volume":"140","author":"Torke","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00923_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s40268-024-00468-4","article-title":"Comparative CNS pharmacology of the Bruton's Tyrosine Kinase (BTK) inhibitor tolebrutinib versus other BTK inhibitor candidates for treating multiple sclerosis","volume":"24","author":"Turner","year":"2024","journal-title":"Drugs R&D"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54430-8","article-title":"BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis","volume":"15","author":"Gruber","year":"2024","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib23","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s12974-024-03267-5","article-title":"Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways","volume":"21","author":"Langlois","year":"2024","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12974-023-02877-9","article-title":"Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis","volume":"20","author":"Nuesslein-Hildesheim","year":"2023","journal-title":"J Neuroinflammation"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00923_bib25","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1021\/acs.jmedchem.9b01916","article-title":"Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of bruton's tyrosine kinase","volume":"63","author":"Angst","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.neurot.2026.e00923_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177747","article-title":"Next generation Bruton's tyrosine kinase inhibitors - characterization of in vitro potency and selectivity","volume":"1002","author":"Pulz","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.neurot.2026.e00923_bib27","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00923_bib28","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.25508","article-title":"Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis","volume":"86","author":"van Langelaar","year":"2019","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00923_bib29","article-title":"T-bet+ CXCR3+ B cells drive hyperreactive B-T cell interactions in multiple sclerosis","volume":"6","author":"Jelcic","year":"2025","journal-title":"Cell Rep Med"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00923_bib30","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.188543","article-title":"Early multiple sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling EBV-induced phenotypes","volume":"10","author":"SoRelle","year":"2025","journal-title":"JCI Insight"},{"issue":"47","key":"10.1016\/j.neurot.2026.e00923_bib31","doi-asserted-by":"crossref","first-page":"eade6844","DOI":"10.1126\/sciadv.ade6844","article-title":"Gammaherpesvirus infection drives age-associated B cells toward pathogenicity in EAE and MS","volume":"8","author":"Mouat","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.neurot.2026.e00923_bib32","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41586-025-09378-0","article-title":"EBV induces CNS homing of B cells attracting inflammatory T cells","volume":"646","author":"Laderach","year":"2025","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00923_bib33","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/ana.22081","article-title":"B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity","volume":"68","author":"Weber","year":"2010","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00923_bib34","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1096\/fj.04-2030fje","article-title":"An elevated matrix metalloproteinase (MMP) in an animal model of multiple sclerosis is protective by affecting Th1\/Th2 polarization","volume":"19","author":"Weaver","year":"2005","journal-title":"FASEB J"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00923_bib35","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1016\/j.celrep.2018.08.060","article-title":"Multimodal enhancement of remyelination by exercise with a pivotal role for oligodendroglial PGC1alpha","volume":"24","author":"Jensen","year":"2018","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00923_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/glia.23245","article-title":"Mechanisms of lysophosphatidylcholine-induced demyelination: a primary lipid disrupting myelinopathy","volume":"66","author":"Plemel","year":"2018","journal-title":"Glia"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib37","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1189\/jlb.0804477","article-title":"Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction","volume":"78","author":"Giuliani","year":"2005","journal-title":"J Leukoc Biol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00923_bib38","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acn3.67","article-title":"Laquinimod reduces neuroaxonal injury through inhibiting microglial activation","volume":"1","author":"Mishra","year":"2014","journal-title":"Ann Clin Transl Neurol"},{"issue":"15","key":"10.1016\/j.neurot.2026.e00923_bib39","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1523\/JNEUROSCI.1948-20.2021","article-title":"Harnessing the benefits of neuroinflammation: generation of macrophages\/microglia with prominent remyelinating properties","volume":"41","author":"Mishra","year":"2021","journal-title":"J Neurosci"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib40","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13024-024-00723-x","article-title":"An adapted protocol to derive microglia from stem cells and its application in the study of CSF1R-related disorders","volume":"19","author":"Dorion","year":"2024","journal-title":"Mol Neurodegener"},{"key":"10.1016\/j.neurot.2026.e00923_bib41","doi-asserted-by":"crossref","first-page":"314","DOI":"10.3389\/fnmol.2019.00314","article-title":"Inflammatory role of TLR-MyD88 signaling in multiple sclerosis","volume":"12","author":"Zheng","year":"2019","journal-title":"Front Mol Neurosci"},{"issue":"7","key":"10.1016\/j.neurot.2026.e00923_bib42","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1523\/JNEUROSCI.22-07-02451.2002","article-title":"The age-related decrease in CNS remyelination efficiency is attributable to an impairment of both oligodendrocyte progenitor recruitment and differentiation","volume":"22","author":"Sim","year":"2002","journal-title":"J Neurosci"},{"key":"10.1016\/j.neurot.2026.e00923_bib43","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00401-020-02129-7","article-title":"Niacin-mediated rejuvenation of macrophage\/microglia enhances remyelination of the aging central nervous system","volume":"139","author":"Rawji","year":"2020","journal-title":"Acta Neuropathol"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00923_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.160909","article-title":"Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib","volume":"7","author":"Rijvers","year":"2022","journal-title":"JCI Insight"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00923_bib45","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.immuni.2023.02.003","article-title":"B cell receptor signaling in germinal centers prolongs survival and primes B cells for selection","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00923_bib46","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/cyto.a.21096","article-title":"Forward light scatter is a simple measure of T-cell activation and proliferation but is not universally suited for doublet discrimination","volume":"79","author":"Bohmer","year":"2011","journal-title":"Cytometry A"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib47","article-title":"Positive effect of evobrutinib in CNS remyelination models and lack of synergy with clemastine-a dose response study","volume":"11","author":"Martin","year":"2025","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00923_bib48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S1474-4422(21)00063-6","article-title":"Cellular immunology of relapsing multiple sclerosis: interactions, checks, and balances","volume":"20","author":"Bar-Or","year":"2021","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2026.e00923_bib49","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N Engl J Med"},{"issue":"11-12","key":"10.1016\/j.neurot.2026.e00923_bib50","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult Scler"},{"issue":"16","key":"10.1016\/j.neurot.2026.e00923_bib51","doi-asserted-by":"crossref","first-page":"eadt8199","DOI":"10.1126\/sciadv.adt8199","article-title":"Critical roles of chronic BCR signaling in the differentiation of anergic B cells into age-associated B cells in aging and autoimmunity","volume":"11","author":"Imabayashi","year":"2025","journal-title":"Sci Adv"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13041-024-01077-7","article-title":"The brain cytokine orchestra in multiple sclerosis: from neuroinflammation to synaptopathology","volume":"17","author":"Amoriello","year":"2024","journal-title":"Mol Brain"},{"issue":"8","key":"10.1016\/j.neurot.2026.e00923_bib53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1007\/s00018-022-04433-9","article-title":"Age-associated B cells in autoimmune diseases","volume":"79","author":"Mouat","year":"2022","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00923_bib54","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1352458512451510","article-title":"Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis","volume":"19","author":"Tutuncu","year":"2013","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurot.2026.e00923_bib55","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1016\/j.immuni.2019.04.004","article-title":"T-bet transcription factor promotes antibody-secreting cell differentiation by limiting the inflammatory effects of IFN-gamma on B cells","volume":"50","author":"Stone","year":"2019","journal-title":"Immunity"},{"issue":"Pt 5","key":"10.1016\/j.neurot.2026.e00923_bib56","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/brain\/awp070","article-title":"The relation between inflammation and neurodegeneration in multiple sclerosis brains","volume":"132","author":"Frischer","year":"2009","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00923_bib57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.cell.2018.08.011","article-title":"Memory B cells activate brain-homing, autoreactive CD4(+) T cells in multiple sclerosis","volume":"175","author":"Jelcic","year":"2018","journal-title":"Cell"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T20:26:06Z","timestamp":1780777566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1878747926000930"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00923","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigations of remibrutinib in models pertinent to multiple sclerosis","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00923","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00923"}}